These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30559132)

  • 21. Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
    Wang P; Liu J; Tan X; Yang F; McCabe J; Zhang J
    Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):397-410. PubMed ID: 37357226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
    Mu S; Tang Z; Novotny W; Tawashi M; Li TK; Ou Y; Sahasranaman S
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):391-399. PubMed ID: 31875923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
    Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
    Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
    Laille E; Patel M; Jones SF; Burris HA; Infante J; Lemech C; Liu L; Arkenau HT
    J Clin Pharmacol; 2015 Dec; 55(12):1378-85. PubMed ID: 26053962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
    Dirix L; Swaisland H; Verheul HM; Rottey S; Leunen K; Jerusalem G; Rolfo C; Nielsen D; Molife LR; Kristeleit R; Vos-Geelen J; Mau-Sørensen M; Soetekouw P; van Herpen C; Fielding A; So K; Bannister W; Plummer R
    Clin Ther; 2016 Oct; 38(10):2286-2299. PubMed ID: 27745744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
    Xu H; O'Gorman M; Tan W; Brega N; Bello A
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of drug-drug interactions of pemigatinib in healthy participants.
    Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1887-1897. PubMed ID: 34282472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
    Meneses-Lorente G; Fowler S; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Mercier F; Ullah M; Umehara K; Brink A; Buchheit V; Zwanziger E; Phipps A; Djebli N
    Invest New Drugs; 2022 Feb; 40(1):68-80. PubMed ID: 34417912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eravacycline for the treatment of patients with bacterial infections.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Apr; 54(4):245-254. PubMed ID: 29869646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
    Hoch M; Huth F; Sato M; Sengupta T; Quinlan M; Dodd S; Kapoor S; Hourcade-Potelleret F
    Clin Transl Sci; 2022 Jul; 15(7):1698-1712. PubMed ID: 35616006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.
    Chen J; Stringer R; Shah B; Gu J; Zhang Y; Hackling M; Prince W; Woessner R
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1253-1263. PubMed ID: 35962468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
    Abbas R; Boni J; Sonnichsen D
    Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study.
    Hu X; Hsieh CY; Zhang Y; Liu W; Xu S; Cai SX; Liu L; Zhang M; Shi H; Zhang H; Liu P; Li X; Xu P
    Br J Clin Pharmacol; 2023 Jun; 89(6):1767-1779. PubMed ID: 36458825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants.
    Miao S; Bekker P; Armas D; Lor M; Han Y; Webster K; Trivedi A
    Clin Pharmacol Drug Dev; 2024 May; 13(5):517-533. PubMed ID: 38423992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.
    Li X; Shelton MJ; Wang J; Meade J; Ruiz-Soto R
    Clin Pharmacol Drug Dev; 2022 Oct; 11(10):1165-1176. PubMed ID: 35560823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
    Hu C; Zhang Y; Pei T; Liu P; Zhang L
    Cancer Chemother Pharmacol; 2023 Jun; 91(6):523-529. PubMed ID: 37166499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers.
    Liu L; Li W; Yang L; Guo ZT; Xue H; Xie NJ; Chen XY
    Acta Pharmacol Sin; 2022 Apr; 43(4):1082-1090. PubMed ID: 34267345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.